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Background: Breathlessness is common in advanced cancer. The Breathlessness Intervention Service (BIS) is
a multi-disciplinary complex intervention theoretically underpinned by a palliative care approach, utilising
evidence-based non-pharmacological and pharmacological interventions to support patients with advanced disease.
We sought to establish whether BIS was more effective, and cost-effective, for patients with advanced cancer and
their carers than standard care.
Methods: A single-centre Phase III fast-track single-blind mixed-method randomised controlled trial (RCT) of BIS
versus standard care was conducted. Participants were randomised to one of two groups (randomly permuted blocks).
A total of 67 patients referred to BIS were randomised (intervention arm n = 35; control arm n = 32 received BIS after a
two-week wait); 54 completed to the key outcome measurement. The primary outcome measure was a 0 to 10
numerical rating scale for patient distress due to breathlessness at two-weeks. Secondary outcomes were evaluated
using the Chronic Respiratory Questionnaire, Hospital Anxiety and Depression Scale, Client Services Receipt Inventory,
EQ-5D and topic-guided interviews.
Results: BIS reduced patient distress due to breathlessness (primary outcome: −1.29; 95% CI −2.57 to −0.005; P = 0.049)
significantly more than the control group; 94% of respondents reported a positive impact (51/53). BIS reduced fear and
worry, and increased confidence in managing breathlessness. Patients and carers consistently identified specific and
repeatable aspects of the BIS model and interventions that helped. How interventions were delivered was important.
BIS legitimised breathlessness and increased knowledge whilst making patients and carers feel ‘not alone’. BIS had a
66% likelihood of better outcomes in terms of reduced distress due to breathlessness at lower health/social care costs
than standard care (81% with informal care costs included).
Conclusions: BIS appears to be more effective and cost-effective in advanced cancer than standard care.
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Trial registration: RCT registration at ClinicalTrials.gov NCT00678405 (May 2008) and Current Controlled Trials
ISRCTN04119516 (December 2008).
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Mixed methodsBackground
Breathlessness (dyspnoea) is a common distressing symp-
tom of advanced cancer, impacting physically, emotionally
and socially on patients and families [1]. Occurring in 90%
of lung cancer and 50% to 70% of all cancers, its preva-
lence increases rapidly towards the end of life [2].
The experience of breathlessness is complex [3]. Given
its multifactorial causes and multidimensional impacts
[2], and absence of a single effective palliative treatment,
complex interventions are indicated. Early intervention
models used non-pharmacological single-disciplinary
approaches [4-6]. More recent models are multi-disciplin-
ary [7], utilising evidence-based pharmacological [8-10]
and non-pharmacological [11-13] component interven-
tions [14,15]. Few have been evaluated with randomised
controlled trial (RCT) methodology.
The Breathlessness Intervention Service (BIS) is a
multi-disciplinary complex intervention combining non-
pharmacological and pharmacological interventions to
support breathless patients with advanced disease, theor-
etically underpinned by a palliative care approach [16-18].
Developed and evaluated [1,19-22] using the Medical
Research Council (MRC) framework for complex inter-
ventions [23], it has undergone a Phase III RCT with two
sub-protocols: one for advanced cancer and one for
advanced non-malignant disease (differing service model
for each) [24]. This paper reports the findings of the sub-
protocol for advanced cancer in relation to the following
research questions:
1. Is BIS more effective than standard care for patients
with intractable breathlessness from advanced
malignant disease?
2. Does it reduce patient and carer distress due to
breathlessness and increase patients’ sense of
mastery of the symptom?
3. What are the experiences and views of those who
use BIS (patients and their informal carers)?
4. Is BIS cost-effective?Methods
A detailed study protocol [24] and detailed intervention
description [16,17] are published elsewhere. Box 1 outlines
the two-week intervention for advanced cancer (interven-
tion duration determined by disease trajectory). The BIS
team comprises: a palliative care medical consultant (withdedicated clinical sessions and a research interest in
breathlessness), a clinical specialist occupational therapist
(lead clinician for the service), a clinical specialist physio-
therapist and an administrator. Each professional contrib-
utes their individual strengths and skills in particular
areas, but all are able to deliver the core interventions out-
lined in Box 1, using a psychologically-informed approach.
At a weekly multidisciplinary team meeting cases are allo-
cated to the most appropriate professional based on infor-
mation derived from the referral; many patients receive
visits from at least two professionals on the team. The
intervention is delivered predominantly in the home-
setting with visits typically lasting 1 to 1.5 hours. Visits
include interventions relevant to that person (outlined
in Box 1) and formulation of an individually-tailored exer-
cise plan, for example, walking incrementally increasing
distances in their local environment using a handheld fan
to manage breathlessness (the first attempt would be ac-
companied by a member of the BIS team). Further details
can also be found on the BIS website [18].
Standard care was defined as specialist outpatient ap-
pointments in secondary care (for example, oncology)
which may include specialist nurse input, and primary
care services. Key aspects of study design, sampling, out-
come measures, data collection and analysis for the ad-
vanced cancer sub-protocol are outlined below.
Study design
We recruited patients with advanced cancer referred
to BIS into a Phase III mixed-method single-blind
pragmatic fast-track (waiting list) RCT of BIS versus
standard care (November 2008 to January 2012). Ethical
approval was given by by Cambridgeshire 2 NHS
REC (Ref:08/H0308/157); RCT registration at Clinical-
Trials.gov NCT00678405 and Current Controlled Trials
ISRCTN04119516.
Randomisation and blinding
Participants were randomised to one of two groups using
randomly permuted blocks of random size two, four and
six, generated by the study statistician and concealed
within sealed opaque envelopes until allocation notifi-
cation by the intervention deliverer. The fast-track (inter-
vention) group received BIS immediately; the waiting-list
(control) group received BIS after two-weeks. All parti-
cipants received standard, including palliative, care. Data
Box 1: Service model for Breathlessness Intervention
Service (BIS) for patients with advanced cancer
The Breathlessness Intervention Service (BIS) is a multi-disciplinary
complex intervention combining non-pharmacological and
pharmacological interventions to support breathless patients with
advanced disease, theoretically underpinned by a palliative care
approach. As such, it is a flexible intervention, responsive to need,
but with a minimum set of core components. Consultations
usually occur in the patient’s own home.
Core components for patients with advanced cancer:
BIS team: Palliative Care Medical Consultant; Clinical Specialist
Occupational Therapist; Clinical Specialist Physiotherapist
Medical assessment: All reviewed at Multi-Disciplinary Team
(therefore all have MD review) but seen by doctor only if complex
medical problems or intractable medical/psychosocial problems
First appointment: Maximum wait of one week for first
appointment
Range of face-to-face visits: one to four
Range of telephone contacts (with patient/primary care staff):
four to six
Average length of service contact: two weeks
Service outcome measures collected at first assessment:
Numerical Rating Scale (NRS) for breathlessness, emotion and
confidence at first and last assessment; Physiological measures,
for example, oxygen saturation, heart rate
Non-pharmacological interventions: Most patients seeing
service are mobile and breathless and, therefore, most patients
have non-pharmacological interventions
Pharmacological interventions: As indicated after review by doctor
First stage interventions (selection and application as
clinically indicated):
Selective use and application of these interventions: explanation
and reassurance; hand-held fan; breathing control; activity
pacing and exercise; anxiety management; psychological
support; information fact sheets; emergency plan; positioning to
reduce work of breathing (rest, recovery and activity); education
to patient, carer and health care generalists; lifestyle adjustment;
individualised exercise plan; relaxation and visualisation; airway
clearance techniques; advice regarding nutrition and hydration;
support to family and patient to utilise education and
selfsupport programmes; sleep hygiene; brief cognitive therapy;
pharmacological review; well-being intervention; formal
relaxation therapy; mindfulness CD; referral to specialist services
(see below)
Second stage interventions:
Second stage interventions likely to be applied concurrently
with first stage interventions: pharmacological review, for
example, low dose opioids, antidepressants, anxiolytics; referral
to specialist services (see below); referral for LTOT or SBOT
assessment; acupuncture
Other symptom management: Frequently required
Documentation: individualised patient plan; detailed letter to
patient of record of consultations with all BIS clinicians;
discharge summary to referrer with copies to GP, specialist
services the patient was already in contact with (for example,
respiratory physicians), other involved health care professionals
(for example, district nurses, nursing home care staff);
supplementary medical letters more common
Referrals: Palliative care specialist service (note: rapid access
available); Community therapists; Hospice day services;
Pulmonary rehabilitation; other specialist assessment; community
groups; charitable and self-help groups, for example, British
Legion, Age UK, Macmillan
[LTOT, long term oxygen therapy; SBOT, short burst oxygen
therapy]
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allocation for the collection of primary and key second-
ary outcomes at the key measurement point, that is,
planned unblinding occurred during the two-week fol-
low up interview (t3) only after collection of this outcome
data and prior to qualitative data collection about the
intervention.Participants
Consecutive cancer patients referred to BIS (from primary
or secondary care) were invited to participate by letter.
Patients were eligible if they met BIS referral criteria (that
is, diagnosed appropriately-treated cause of breathless-
ness, troubled by breathlessness in spite of optimisa-
tion of underlying illness, and might benefit from a
self-management programme) and excluded if they
had received BIS previously. Recruited patients were
asked to identify who gave them the most help and
support at home and these informal carers were also
invited to participate. All participating patients and
informal carers gave informed consent. Patients who
were unwilling to participate in the trial continued to
have access to BIS.Sample size
A sample size of 60 randomised patients (26 analysed per
arm, allowing for dropout) provided 80% power to detect a
2-point difference in mean distress at two-weeks between
groups (SD = 2.5, alpha = 5%), with increased precision
anticipated from adjustment for baseline.
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Patient distress due to breathlessness [4,5] (the primary
outcome on which the trial was powered) was measured
using a numerical rating scale (NRS). Other key patient-
reported variables included disease-specific health related
quality of life (Chronic Respiratory Questionnaire: CRQ
[25]), and anxiety and depression (Hospital Anxiety and
Depression Scale: HADS [26]). Key carer-reported out-
come measures included an NRS for carer distress due to
patient breathlessness and HADS. A generic health status
measure (EQ-5D [27]) and measure of service use (Client
Services Receipt Inventory (CSRI) [28]) were adminis-
tered for health economic analyses. Brief qualitative topic-
guided interviews were also conducted with all patients
and carers to explore expectations and experiences of BIS.
All outcomes were participant-reported; the full outcomes
list is reported elsewhere [24].
Data collection
Participating patients and carers completed a baseline
interview (t1: week 1) before randomisation. These mixed-
method interviews included the quantitative patient- and
carer-reported measures and qualitative interviews descri-
bed above (carers were interviewed separately where pos-
sible). A two-week follow up interview (t3: week 3) was
designed to represent completion of BIS for the interven-
tion arm, or end of the waiting-list period prior to BIS
for controls. A final interview (t5: week 5) was conducted
four-weeks from baseline; this represented two-weeks
after BIS for the intervention arm and completion of BIS
for controls. All interviews were conducted in home-
settings.
Analysis
Complete case intention-to-treat analyses were conducted
using a linear regression model; each outcome was ad-
justed for its baseline. A 5% level of statistical significance
was used. Costs were calculated combining service use
data (CSRI) for eight-weeks and two-weeks prior to base-
line and t3, respectively, with UK 2011/2012 unit costs
[29]. Informal care (unpaid hours/week from family/
friends performing specific tasks) was valued at average
UK wages (£11.21/hour) [30]. Costs of BIS visits were esti-
mated at £91 (based on specialist nurse contacts which
averaged the rehabilitation specialists’ wages) and phone
contacts at one-quarter of this. Costs were compared
using regression models, controlling for baseline, and
using bootstrap methods with 1,000 resamples to address
the likely skewed distribution. Sensitivity analyses were
performed around these key costs by increasing/decreas-
ing costs by 25% and 50%. Costs, with and without infor-
mal care, were combined with the primary outcome and
EQ-5D-derived quality-adjusted life years (QALYs), with
uncertainty explored using cost-effectiveness planes [31].Cost-effectiveness planes are a graphical way of comparing
one intervention to another or to usual care. The vertical
axis of the plane shows the extra costs incurred by an
intervention while the horizontal axis shows the extra out-
comes achieved; both of these could be positive or nega-
tive resulting in four quadrants on the plane. Bootstrap
methods can then be used to produce a large number of
cost and outcome combinations which can be plotted on
the plane to show the probability of the intervention
resulting in higher costs and better outcomes, higher costs
and worse outcomes, lower costs and better outcomes or
lower costs and worse outcomes.
Qualitative interview data were transcribed and anon-
ymised. Two analytic approaches were taken to the com-
prehensive qualitative dataset. First, transcripts of all post-
intervention interviews (fast-track group t3s and control
t5s; n = 53, no qualitative interview for one patient) were
categorised into one of three intervention impact levels by
three analysts working independently (Level 1: Significant
impact - clearly stated BIS made a difference; Level 2:
Some impact - no major change recognised, but valued
specific aspects of BIS; Level 3: No impact – BIS made no
difference at all). Categorisation commenced with a small
number of interviews. Analysts then compared categorisa-
tions, discussing and resolving differences, clarifying level-
definitions and data interpretation, before repeating for all
remaining interviews.
Second, as qualitative analysis of this sized dataset
(n = 53) would be unmanageable, 20 patient (and associ-
ated carer) intervention arm transcripts were purposefully
sampled against a novel stratified four-cell matrix of pri-
mary outcome changes by t3, to achieve a maximum
diversity sample [32]. The four cells represented: (Cell 1)
patients who improved most on primary outcome (who,
predictably, had high baseline scores; Biggest Improvers);
(Cell 2) patients with high baseline scores (to match Cell 1)
but who improved least (Limited Improvers); (Cell 3) pa-
tients who worsened (who transpired to have low-middling
baseline scores; Worseners); and (Cell 4) patients with
closest match to Cell 3 baseline scores but who improved
most (Moderate Improvers). Anonymised interview tran-
scripts for this purposive sample were imported into
NVivo software [33], to facilitate framework analysis [34].
This principally descriptive analysis explored the nature of
BIS impacts, which aspects were valued, and possible
mechanisms of impact.
Results
Figure 1 (CONSORT diagram) illustrates randomisation
of 67 patients; 54 completed the trial to key outcome
measurement (t3). Thirteen patients withdrew due to de-
terioration prior to t3: seven and six from intervention
and control arms, respectively, (including two intervention
arm deaths), with very similar mean baseline distress due
Figure 1 CONSORT flow diagram.
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withdrawals and 5.86 for the control arm withdrawals.
The intent was for researchers to remain blinded to
group allocation until after measurement of the primary
outcome at t3; this was achieved for 52% (28/54) of the
patients. The remainder unintentionally unblinded resear-
chers earlier in the t3 interview either by inadvertently
mentioning contact with BIS or by BIS resources (for ex-
ample, information sheets) being visible to the researcher
in the patient’s home.
Baseline characteristics were well matched across trial
arms (Table 1). Patients were predominantly older, fe-
male and living with others; lung was the commonest
cancer site, then breast. Patients’ mean level of anxiety
(7.52) was higher by one-third of a standard deviation
compared with the mean population norm (mean popula-
tion norm for anxiety 6.14; SD = 3.76) [35] and their mean
level of depression (6.26) was notably higher (mean popu-
lation norm for depression 3.68; SD = 3.07) by 0.84 SD
of the norm distribution. Just under half had clinically-
meaningful anxiety scores and about a quarter clinically-
meaningful depression scores. Breathlessness, performance
status and co-morbidity were as anticipated. Patient
‘distress due to breathlessness’ and CRQ domain-scores
were similar across trial arms.Carers were predominantly older women, and about a
third were employed. Carers’ mean level of anxiety was
moderately higher than population norms by 0.30 SD of
the norm distribution [35] and depression was comparable
(higher by 0.06 SD). About half had clinically-meaningful
anxiety scores and just under a quarter had clinically-
meaningful depression scores. Carer ‘distress due to patient
breathlessness’ was lower than patients’, but similar across
trial arms.
Changes in patient distress due to breathlessness
Comparison of change in patient distress due to breath-
lessness (primary outcome; NRS range 0 to 10) by the
key outcome measurement point (t3) showed that patients
randomised to the intervention arm achieved a signifi-
cantly greater, 1.68-point, reduction compared with 0.23-
point reduction for controls: adjusted difference of −1.29
(95% CI: −2.57 to −0.005), P = 0.049 (Table 2). There was
little change in carer distress.
Change in mastery of breathlessness, anxiety and
depression
Mean CRQ mastery scores improved only negligibly by
t3 on the intervention arm and remained stable for con-
trols (not statistically significant; Table 2). No significant
Table 1 Baseline characteristics of patients and carers by arm, BIS Phase IIIm
Baseline characteristics Mean (SD) or % (number)
Intervention arm Control arm Total
Patient baseline characteristics
Age (years) 70 (9.4) 67 (13.3) 69 (11.5)
Sex (female) 59% (21) 62% (20) 61% (41)
Lives alone 34% (12) 28% (9) 31% (21)
Cancer site (primary):
Lung 45% (16) 54% (17) 49% (33)
Breast 25% (9) 13% (4) 19% (13)
Rectal/bowel 6% (2) 6% (2) 6% (4)
Prostate 6% (2) 3% (1) 4% (3)
Lymphoma 3% (1) 6% (2) 4% (3)
Mesothelioma 3% (1) 6% (2) 4% (3)
Gastro-oesophageal junction 3% (1) 3% (1) 3% (2)
Renal 3% (1) 3% (1) 3% (2)
Endometrial 0% (0) 3% (1) 2% (1)
Hepatocellular 3% (1) 0% (0) 2% (1)
Bladder 0% (0) 3% (1) 2% (1)
Unknown primary 3% (1) 0% (0) 2% (1)
Charlson Co-Morbidity Index (0 to 9)a 6.34 (2.30) 5.63 (2.14) 6.00 (2.24)
Australia-modified Karnofsky Performance Scale (0 to 100)b,c 71.1 (12.6) 74.1 (14.8) 72.5 (13.6)
Modified Borg: breathlessness at rest (0 to 10)a 1.69 (1.09) 1.39 (1.77) 1.55 (1.45)
Modified Borg: breathlessness on exertion (0 to 10)a 5.27 (2.18) 5.13 (2.21) 5.20 (2.18)
NRS worst breathlessness 24 hours (0 to 10)a 4.97 (2.46) 4.19 (2.28) 4.60 (2.39)
NRS breathlessness now (0 to 10)a 2.29 (1.74) 1.81 (1.38) 2.06 (1.59)
NRS average breathlessness 24 hours (0 to 10)a 3.83 (1.67) 3.38 (1.93) 3.61 (1.80)
NRS distress due to breathlessness (0 to 10)a 5.17 (2.81) 4.94 (2.84) 5.06 (2.81)
Anxiety score (HADS) (0 to 21)a 6.97 (4.01) 8.09 (3.31) 7.52 (3.70)
Depression score (HADS) (0 to 21)a 6.61 (2.73) 5.91 (2.99) 6.26 (2.87)
Anxiety (HADS)a:
Normal (0 to 7) 55% (18) 53% (17) 54% (35)
Mild (8 to 10; possible clinical disorder) 27% (9) 19% (6) 23% (15)
Moderate (11 to 14; probable clinical disorder) 15% (5) 25% (8) 20% (13)
Severe (15 to 21; probable clinical disorder) 3% (1) 3% (1) 3% (2)
Depression (HADS)a:
Normal (0 to 7) 70% (23) 78% (25) 74% (48)
Mild (8 to 10; possible clinical disorder) 21% (7) 9% (3) 15% (10)
Moderate (11 to 14; probable clinical disorder) 9% (3) 13% (4) 11% (7)
Severe (15 to 21; probable clinical disorder) 0% (0) 0% (0) 0% (0)
CRQ dyspnoea score (1 to 7)b 3.42 (0.99) 3.39 (0.98) 3.41 (0.98)
CRQ fatigue score (1 to 7)b 3.38 (1.33) 3.20 (1.07) 3.29 (1.20)
CRQ emotional function score (1 to 7)b 4.43 (1.02) 4.46 (1.30) 4.35 (1.06)
CRQ mastery score (1 to 7)b 4.57 (1.15) 4.46 (1.30) 4.52 (1.22)
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Table 1 Baseline characteristics of patients and carers by arm, BIS Phase IIIm (Continued)
Number of respondents (patients) 33-35 32 65-67
Carer baseline characteristics
Carer age (years) 65.6 (13.4) 63.5 (12.2) 64.6 (12.7)
Carer sex (female) 70% (14) 67% (14) 68% (28)
Carer employment status:
Employed – full time 11% (2) 24% (5) 18% (7)
Employed – part time 22% (4) 5% (1) 13% (5)
Retired 61% (11) 57% (12) 59% (23)
Other (e.g. unemployed due to illness/student) 6% (1) 14% (3) 10% (4)
NRS carer distress due to patient breathlessness (0 to 10)a 3.56 (2.44) 3.86 (2.82) 3.72 (2.62)
Carer anxiety score (HADS) (0 to 21)a 7.89 (5.33) 6.76 (3.59) 7.28 (4.45)
Carer depression score (HADS) (0 to 21)a 3.39 (3.91) 4.29 (2.93) 3.87 (3.40)
Carer anxiety (HADS)a:
Normal (0 to 7) 44% (8) 57% (12) 51% (20)
Mild (8 to 10; possible clinical disorder) 17% (3) 24% (5) 21% (8)
Moderate (11 to 14; probable clinical disorder) 28% (5) 19% (4) 23% (9)
Severe (15 to 21; probable clinical disorder) 11% (2) 0% (0) 5% (2)
Carer depression (HADS)a:
Normal (0 to 7) 78% (14) 76% (16) 77% (30)
Mild (8 to 10; possible clinical disorder) 22% (4) 19% (4) 20% (8)
Moderate (11 to 14; probable clinical disorder) 0% (0) 5% (1) 3% (1)
Severe (15 to 21; probable clinical disorder) 0% (0) 0% (0) 0% (0)
Number of respondents (carers) 18-20 19-21 39-41
No carer/no carer interview 43% (15) 34% (11) 39% (26)
aHigh score is worse; bhigh score is better; ca score of 70 represents ‘cares for self yet unable to carry on normal activity or to do active work’. BIS, Breathlessness
Intervention Service; CRQ, Chronic Respiratory Questionnaire; HADS, Hospital Anxiety and Depression Score; NRS, numerical rating scale.
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CRQ domains (dyspnoea, fatigue or emotional function).
Mean anxiety scores (HADS) remained fairly stable to t3
(both arms). Mean depression scores decreased slightly
by t3 in the intervention arm, increasing slightly for con-
trols (not statistically significant). There was little change
in other patient or carer outcomes.
Reported benefit of BIS
Categorisation of qualitative interviews inferred that for
68% (n = 36) of patients, or patient-carer dyads, BIS had
had a significant impact (Level 1). A further 28% (n = 15)
indicated BIS had had some impact (that is, no major
change, but they valued specific aspects of BIS; Level 2)
and 4% (n = 2) reported no impact (Level 3).
Table 3 shows the Impact Categorisation Levels for the
purposively-sampled qualitative interviews, sampled for
maximum diversity of change on primary outcome to t3.
Given the skewed distribution of the levels it is unsurpris-
ing that most were Level 1 and 2, even among primary
outcome ‘Worseners’ (Cell 3).Qualitative analysis of the purposively-sampled inter-
views identified both the nature of BIS impacts and which
aspects of the BIS model were valued, as well as the pos-
sible mechanisms of impact. Impacts described included
patients and carers noting reductions in fear, anxiety,
worry and feelings of panic, and greater confidence about
breathlessness. Patients reported managing their breath-
lessness better, and some carers living separately from
patients reported that the latter contacted them less.
Patients and carers valued specific aspects of the
BIS model. The multi-disciplinary staff expertise was
repeatedly noted: their knowledge about breathlessness,
and strategies suggested to manage it, made clear they
understood difficulties of life with breathlessness. Partici-
pants described particularly helpful characteristics of
BIS staff, such as being relaxed and easy to talk to,
listening and reassuring. They valued the time BIS
gave them to talk about breathlessness with an expert.
Being seen at home was especially helpful, as was the posi-
tive ‘can do’ approach of BIS and unexpected attention
given to carers.
Table 2 Changes in patient distress due to breathlessness (primary outcome), mastery of breathlessness, anxiety and
depression, by trial arm
Trial arms and outcomes t1a
Mean (SD)
t3
Mean (SD)
t5
Mean (SD)
Difference in mean t3 adjusted
for baseline (I minus C)
With 95% confidence
interval
P-value
Control arm (waiting-list) Baseline Completed
control
Completed
intervention
Intervention arm (fast-track) Baseline Completed
intervention
Post-intervention
Primary outcome: NRS distress due to breathlessness (0 to 10)b
Control arm (waiting-list) 4.65 (2.99) 4.42 (3.01) 2.58 (1.82)
−1.29 (−2.57, -0.005) P = 0.049
Intervention arm (fast-track) 5.11 (2.78) 3.43 (2.95) 3.65 (3.07)
Key secondary outcomes:
CRQc Mastery (1 to 7)
Control arm (waiting-list) 4.71 (1.27) 4.72 (1.21) 4.72 (1.12) 0.20 (−0.35, 0.76) P = 0.47
Intervention arm (fast-track) 4.53 (1.13) 4.81 (1.29) 4.72 (1.18)
HADSb anxiety (0 to 21)
Control arm (waiting-list) 7.88 (3.41) 7.85 (3.59) 7.61 (3.96) 0.017 (−1.52, 1.56) P = 0.98
Intervention arm (fast-track) 7.00 (4.08) 7.07 (5.05) 6.77 (3.52)
HADSb depression (0 to 21)
Control arm (waiting-list) 5.88 (2.94) 6.23 (2.89) 6.13 (2.80) −0.30 (−1.79, 1.20) P = 0.69
Intervention arm (fast-track) 6.38 (2.17) 6.22 (3.36) 6.27 (3.12)
No. of respondents 52-54 53-54 45-47
aFor those with a t3 score; bhigh score is worse; chigh score is better. CRQ, Chronic Respiratory Questionnaire; HADS, Hospital Anxiety and Depression Score; NRS,
numerical rating scale; SD, standard deviation.
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BIS that were therapeutic including: providing and teach-
ing use of a handheld fan; encouragement of exercise
(including pedometer provision/goal-setting); coaching in
breathing techniques, positioning, pacing and relaxation
(including provision of BIS’ mindfulness-based body-scan
CD and teaching visualisation techniques); occupationalTable 3 Purposively sampled t3 qualitative interviews (interv
Change in patient NRS distress due to breathlessnessa (primary outcom
Cell 1: Biggest Improvers (from high baseline scores)
533: NRS distress reduced from 8–1 (Level 2)
564: NRS distress reduced from 7–1 (Level 1)
583: NRS distress reduced from 9–3 (Level 1)
648: NRS distress reduced from 7–1 (Level 1)
603: NRS distress reduced from 5–0 (Level 1)
Cell 3: Worseners (who turned out to have a low-middling
baseline scores)
563: NRS distress increased from 4–9 (Level 2)
578: NRS distress increased from 3–7 (Level 2)
569: NRS distress increased from 5–7 (Level 1)
612: NRS distress increased from 5–7 (Level 1)
559: NRS distress increased from 5–6 (Level 2)
aHigh score is worse. Level 1 = significant impact; Level 2 = some impact; Level 3 = n
identity numbers.therapy aids; information and education (verbal, printed
sheets and hand-drawn diagrams) - learning that ‘being
breathless won’t kill me’ was cited as particularly liberat-
ing. Other valued actions included medication changes,
referral-on to other services (for example, hospice day
care) and advising on daily strategies to ease breathless-
ness (often described as ‘lots of little things’).ention arm) and their Impact Categorisation Levels
e) t1 to t3 (and Impact Categorisation Level)
Cell 2: Limited Improvers (high baseline score Cell 1 matches
who improved the least)
530: NRS distress reduced from 10–8 (Level 1)
591: NRS distress: reduced from 10–8 (Level 1)
624: NRS distress reduced from 10–8 (Level 2)
536: NRS distress reduced from 5–3 (Level 1)
630: NRS distress unchanged 4–4 (Level 2)
Cell 4: Moderate Improvers (closest baseline score Cell 3 matches
who improved the most)
501: NRS distress reduced from 4–1 (Level 1)
637: NRS distress reduced from 3–0 (Level 3)
616: NRS distress reduced from 3–1 (Level 1)
658: NRS distress reduced from 8–4 (Level 2)
587: NRS distress reduced from 9–5 (Level 1)
o impact. NRS, numerial rating score. Three-digit numbers = participant
Box 2: Illustrative quotes from purposive sample
about mechanisms of impact and valued interventions
Mechanisms of impact
Mechanism of impact - gaining knowledge:
Patient: ‘she said to me put my lips … like that … and [breathe]
through my mouth. I thought […] ‘how is that going to work?’
[…] but I must be honest, it’s brilliant. Do you know it helps
more than doing it through your nose? […] well I was very
interested, because I went to the bathroom and of course when
I got back I couldn’t breathe […] and I thought ‘well give it go’,
you know, and … […] it does help, it really does. […] I thought
the nose and the mouth was the most important thing for you
to do, but her telling me that and another thing as well, when I
get out of breath, is to put my hand on my tummy … puff puff
puff … and do that, and you know, it’s amazing really, it sounds
so pathetic when you say something … It is simple, it’s not a
thing you’d think of doing [putting] your hands on your tummy
and do that, you wouldn’t … […] She was really helpful’
[530t3pc; Impact Categorisation Level 1 – Significant impact;
Cell 2 – Low Improver on primary outcome]
Mechanism of impact - feeling not alone:
Carer: ‘It’s nice to know it’s there, that if I’ve got any problems or
worries that I can phone up and say ‘I think he’s a lot, lot, lot worse
today, what can I do?’ … you know? […] Because you know …
we’re a long way from [hospital], and you can’t just sort of keep
popping up and going there because it exhausts him anyway …
and it’s nice to know there’s someone at the end of the phone to
say ‘well try this, try this, and if it doesn’t get any better do this …”
[569t3c; Impact Categorisation Level 1 – Significant impact;
Cell 3 – Worsener on primary outcome]
Mechanism of impact - gaining confidence:
Patient: ‘I’ve gained more confidence and like I say, with that fan,
[I] went upstairs […] and whereas I normally sit on the bed and
I’ve got a cylinder of oxygen under the bed, I might have got
that … but I got myself round with just the fan, because she said
‘quite often you think you’re worse than what you are, but if you
had a bit of air in your face’ and […] that did work’
Interviewer: ‘And what did you find most helpful about the Service
so far?’
Patient: ‘Probably the little tips she’s given me really and build
your confidence up’
[536t3pc; Impact Categorisation Level 1 – Significant impact;
Cell 2 – Low Improver on primary outcome]
Valued interventions
Valued intervention - handheld fan:
Patient: ‘…she was really helpful. I mean she’s given me
exercises to do, she’s left me a fan … and she’s told me how to
use that, she’s shown my husband and me how to deal with [it].
[…] if I get breathless the fan will help … I breathe in and blow
out … and blow out […]. I was surprised really because I’ve
used these handheld fans in the summer in the car before I got
this … and I always thought they were just to cool you down!
But I must admit … when she showed me how to use it, at the
time, I found it was very good’
[603t3pc; Impact Categorisation Level 1 – Significant impact; Cell
1 – Big Improver on primary outcome]
Valued intervention - exercise:
Patient: ‘[She] suggested exercising my legs, sort of holding
them up like that […] to try and strengthen my thigh muscles
[…] I can sit here and do what she suggested and it’s certainly
easier to climb the stairs’
[578t3p; Impact Categorisation Level 2 – Some impact; Cell 3 –
Worsener on primary outcome]
Valued intervention - pacing:
Patient: ‘She was saying if you want to do something think about
doing it, don’t just get up and do it, […] because I get up and do it
suddenly I suddenly get breathless and I can’t do it, and one of the
ideas she had was well, if you think about doing something, think
of what the best way of doing it is which isn’t going to make you
breathless and then go about it that way and see what the result
is. And I tried that, so instead of thinking … I want something from
the garage … I’ll go and get it, I think ‘I want something from the
garage, right, I’ll go down there in a minute and pick it up and sort
of get my body working’, and then go and do it, and that doesn’t
stress you as much. Odd little things like that’
[587t3p; Impact Categorisation Level 1 – Significant impact;
Cell 4 – Moderate Improver on primary outcome]
Valued intervention – ‘breathlessness won’t kill me’:
Interviewer: ‘what was the most helpful thing [they] did from
your point of view?’
Patient: ‘[Telling me that] breathlessness is not harmful. […]
because I thought getting out of breath wasn’t good for you. It’s
not good for you, but it’s not going to harm you […] And that
reassures you, because […] you think ‘I’m not going to die, this is
just a blip, you’ll get over it’ […] and now I know what to do, so
she was really helpful. I wouldn’t have known that if I hadn’t seen
her, I would have just gone on thinking ‘oh dear …’ […] and the
panic you see makes you feel worse. If you’re panicked about
something it makes your breathing worse because you breathe
different when you panic. Even you would if you was in a panic,
you would be breathing different. […] and I don’t get that any
more. […] I know how to deal with it [now]’
[603t3pc; Impact Categorisation Level 1 – Significant impact;
Cell 1 – Big Improver on primary outcome]
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http://www.biomedcentral.com/1741-7015/12/194Explanatory analysis suggests it was not only the
provision of these interventions that was important: how
they were delivered was key to their impact. The data
suggest they were delivered through the provision of
knowledge, with specialist expertise, which increased
patients’ and carers’ confidence. For example, some re-
ported receiving handheld fans from other clinicians but
identified the way BIS delivered this intervention as differ-
ent: BIS explained how and when to use the fan and how
it might work, so legitimising what at first appeared an
unlikely effective intervention.
Thus, the mechanism of impact appeared to relate to
improved knowledge, enhancing patients’ and carers’
understanding and their confidence in living with the
symptom. BIS acknowledged, and thereby validated,
breathlessness; patients and carers reported no longer
feeling alone. Box 2 provides illustrative quotes for gaining
knowledge and confidence, and some participant-identified
interventions.
Reviewing transcripts for the categorisation exercise
identified that more than half of patients had further
contacts planned with BIS beyond the key measurementTable 4 Service use and cost in eight-weeks prior to baseline
Service use and cost during the eight-weeks prior to baseline assessme
Formal and informal care Intervention arm (number = 35)
Service Number (%) Mean (SD) contacts Mea
Inpatient 15 (43) 13.0 (12.1) 31
Other hospital care 32 (91) 5.9 (6.3) 7
GP 31 (89) 3.2 (2.3) 1
Nurse 27 (77) 10.4 (19.0) 2
Other health professionals 17 (49) 2.0 (1.1)
Social care 5 (14) 29.6 (30.3) 1
Total formal care costs 44
Informal care 32 (91) 20.4 (18.8) 16
Total costs 61
Service use and cost between baseline and t3
Intervention arm (number = 28)
Service Number (%) Mean (SD) contacts Mea
BIS intervention 27 (96) 1.9 (2.0)
Inpatient 2 (7) 3.0 (2.8) 1
Other hospital care 15 (54) 1.5 (0.8) 1
GP 10 (36) 1.2 (0.6)
Nurse 11 (39) 3.0 (3.8)
Other health professionals 5 (18) 1.2 (0.4)
Social care 4 (14) 4.3 (6.5)
Total formal care costs 4
Informal care 22 (79) 20.3 (20.8) 3
Total costs 7
Costs in 2011/2012 £s. BIS, Breathlessness Intervention Service; GP, general practitioof the primary outcome: 52% (28/54) described planned
contacts beyond t3. Thus, any improvement in the pri-
mary outcome at t3 was early impact and there may have
been further benefit beyond this.
Costs and cost-effectiveness
Table 4 shows contacts with services (face-to-face or tele-
phone) and associated costs. At baseline most patients
received hospital, general practitioner and informal care.
Costs for some individual services were quite different
between arms, but (in common with most other economic
evaluations) zero costs were common and standard devia-
tions high. Total costs at baseline were higher in the inter-
vention arm. Between baseline and t3 more than half
received hospital care (both arms) and fewer in the inter-
vention group used inpatient or informal care (Table 4).
Costs during follow-up were notably lower, mainly due to
the shorter cost-period compared to baseline. Adjusting
for baseline costs, the intervention group had health/social
care costs on average £211 less than controls (95% CI, −
£918 to £310), decreasing to £182 and £154 when inter-
vention costs were increased by 25% and 50%, respectivelyassessment and between baseline and t3
nt
Control arm (number = 32)
n (SD) cost Number (%) Mean (SD) contacts Mean (SD) cost
87 (5807) 16 (50) 8.1 (5.5) 2306 (3208)
12 (827) 31 (97) 4.5 (2.9) 566 (377)
45 (165) 28 (88) 3.5 (1.9) 134 (102)
78 (605) 26 (81) 2.5 (1.9) 63 (72)
42 (59) 15 (47) 1.9 (1.2) 33 (55)
01 (343) 5 (16) 24.8 (48.8) 110 (462)
64 (6017) 3212 (3434)
73 (1690) 32 (100) 25.1 (25.1) 2249 (2248)
37 (6099) 5461 (4393)
Control arm (number = 26)
n (SD) cost Number (%) Mean (SD) contacts Mean (SD) cost
119 (62) 2 (8) 1.5 (0.7) 5 (20)
23 (547) 3 (12) 6.3 (6.8) 418 (1614)
05 (115) 14 (54) 1.4 (0.6) 96 (107)
22 (38) 13 (50) 1.3 (0.5) 27 (32)
37 (96) 12 (46) 1.8 (1.6) 25 (46)
11 (28) 3 (12) 1.0 (0.0) 3 (9)
20 (59) 3 (12) 15.7 (22.9) 45 (190)
36 (604) 618 (1627)
58 (452) 25 (96) 23.4 (25.2) 504 (564)
94 (866) 1121 (1635)
ner; SD standard deviation.
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http://www.biomedcentral.com/1741-7015/12/194(intervention remained dominant). Total costs (including
informal care) were £354 less for the intervention group
(95% CI, −£1020 to £246).
Lower health/social care costs and better primary out-
come results for the intervention arm indicated domin-
ance over the control condition. Cost-effectiveness planes
showed a 66.4% likelihood that the intervention would
have lower health/social care costs and better outcomes in
terms of reduced distress due to breathlessness than the
control condition and a 30.9% likelihood of higher health/
social care costs and better outcomes (likelihood of lower
costs and worse outcomes 1.4%; likelihood of higher costs
and worse outcomes 1.3%). The figures for total costs
(including informal care) were 80.9% and 16.4%, respect-
ively (likelihood of lower costs and worse outcomes 2.2%;
likelihood of higher costs and worse outcomes 0.5%). The
maximum QALY-gain over a two-week period was 0.038.
The intervention resulted in an incremental QALY-gain of
0.0002 (95% CI, −0.001 to 0.002). While technically indi-
cating dominance for the intervention, the difference was
small and variation substantial. This is reflected in the
cost-effectiveness plane showing BIS having a 40.5% likeli-
hood of lower health/social care costs and a greater
QALY-gain than the control condition, a 21.4% likelihood
of higher costs and a greater QALY-gain, a 27.3% likeli-
hood of lower costs and a smaller QALY-gain and a 10.8%
likelihood of higher costs and a smaller QALY-gain. With
informal care included the figures were 50.9%, 11.0%,
32.2% and 5.9%, respectively. The cost-effectiveness planes
are available as supplementary material [see Additional
file 1: Figures S1 to S4].
Discussion
In this Phase III RCT, BIS reduced distress due to
breathlessness in patients with advanced cancer signifi-
cantly more than the control group. When costs were
linked to the primary outcome, the findings indicate BIS
was cost-effective over the follow-up period; however,
this was less apparent when using QALYs, possibly
reflecting the relatively short follow-up period. The rea-
sonably sized effect is a useful indicator of the impact of
BIS and was the primary outcome, but the qualitative
data were more informative for service evaluation. BIS
reportedly made a positive difference to 94% of patients
and carers with impacts including reduced fear and
worry, and increased confidence about breathlessness.
Patients and carers consistently noted specific, identifi-
able and repeatable aspects of the BIS model and a range
of interventions they found helpful in reducing the im-
pact of breathlessness, many of which suggest modula-
tion of central perception [15,36]. Although a list of
interventions the participants found beneficial is useful,
the way these interventions were delivered was import-
ant. BIS appears to work by legitimising breathlessnessand increasing knowledge and confidence whilst making
patients and carers feel ‘not alone’. Henoch et al. [3],
identified the importance of ‘coping capacity’ in helping
lung cancer patients manage the palliative phase; BIS
may be increasing this.
Although we identified modest group-level reduction
in distress due to breathlessness, distress decreased con-
siderably for some individuals but increased for others –
some increase may be anticipated in progressive disease.
As Table 2 demonstrated, these ‘Worseners’ did, how-
ever, continue to report benefit from BIS. This raises the
question of whether the selected quantitative primary
outcome was the most appropriate to measure accurately
the effect of the intervention. Further, any measured im-
pact was early impact as many had further input from BIS
beyond the key measurement point; plus potential added
effects of BIS referrals-on to other services is unknown.
We believe this is the first fast-track RCT in advanced
cancer to attempt to use single-blinding and in this we
were partially successful. Additionally, although trials
increasingly include qualitative elements where appropri-
ate [37], this mixed-method trial was unusual in collecting
qualitative data on all participants, not just a sub-sample.
This enabled quantification of aspects of the qualitative
data and purposive sampling on changes in the primary
outcome.
The trial suffered slow recruitment due to slower
referrals of cancer patients and a higher refusal rate than
anticipated. Thirteen patients were lost to follow up but
were evenly spread across trial arms, with very similar
mean baseline scores, and no data at an intermediate
time-point with which to further assess sensitivity of the
results to the assumptions of the primary analysis ap-
proach. The main result was borderline statistically signifi-
cant; sensitivity analysis to the handling of missing data
would inevitably cast some doubt on the main result;
therefore, this is a limitation. The trial might have bene-
fitted from later timing of the key measurement point to
include more BIS contacts in the analysis of impact sug-
gesting that, in some cases, the BIS intervention may
require slightly longer than two-weeks to be delivered for
patients with advanced cancer (reflecting the interven-
tion’s individualised nature). Longer-term follow up would
have enabled examination of maintenance of benefit.
This trial supports positive findings of earlier studies of
intervention services for breathlessness in advanced cancer
[4-6,38]. The key differences between these and BIS are
that BIS is multidisciplinary, delivered in patients’ homes
and takes a flexible individualised approach to the number
and content of contacts. Recent work by Ellis et al. [39],
suggests this may explain the lower attrition experienced
by BIS than other services. In addition, BIS was more
robustly developed and evaluated due to the availability of
the MRC framework for complex interventions.
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In conclusion, BIS appears to be more clinically-effective,
and cost-effective, for patients with breathlessness in ad-
vanced cancer and their carers than standard care.
Additional file
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social care costs and reduction in patient distress due to breathlessness.
Figure S2. Cost-effectiveness plane based on total costs and reduction in
patient distress due to breathlessness. Figure S3. Cost-effectiveness plane
based on health/social care costs and QALYs. Figure S4. Cost-effectiveness
plane based on total costs and QALYs.
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